Compare Alliant Energy Corporation (LNT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Alliant Energy Corporation trades at $67.51 (market cap $17.36B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Alliant Energy Corporation is far larger — about 2.3× Spyre Therapeutics Inc. Common Stock's market cap, and Alliant Energy Corporation pays a 3.2% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 65 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LNT | SYRE | |
|---|---|---|
Market Cap | $17.36B | $7.52B |
Volume | 1,948,386 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $78.03 | $108.92 |
52-Week Low | $63.21 | $22.18 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $29.46B | $6.52B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $67.51, up 1.58% with a bullish technical signal despite mixed momentum indicators. The company shows solid fundamentals with Q2 2026 earnings beating expectations at $0.65 per share and maintaining 18.45% net margins. Recent news highlights institutional accumulation and a $13.4 billion capital investment plan through 2029 supporting long-term growth. Analyst consensus remains positive with a $75.17 price target and no sell ratings.
LNT presents a favorable risk-reward profile with strong utility operations, consistent dividend growth, and data center demand driving revenue. Key risks include rising debt levels (48.48% debt-to-asset ratio) and interest rate sensitivity. The stock offers defensive value with upside potential to analyst targets, though investors should monitor execution of the large capex plan and regulatory developments.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
